Educational article
Semaglutide and tirzepatide: benefits, side effects and obesity treatment differences
Educational content. It does not replace an individual medical assessment and should not be used for self-medication.

How each medicine works
Semaglutide acts on the GLP‑1 receptor. Tirzepatide acts on GIP and GLP‑1 receptors. They are different active ingredients and each formulation has a specific indication. The decision includes medical history, other medicines and the concern being addressed.
Which benefits have been studied
Trials in adults with obesity have assessed weight reduction and changes in metabolic measures. Some semaglutide formulations also have cardiovascular outcome evidence in defined populations. Ask which benefit was studied with the product you are considering.
What the direct comparison found
SURMOUNT compared injectable tirzepatide and semaglutide in adults with obesity without diabetes. Average weight reduction was greater in the tirzepatide group. The finding describes that trial and needs to be considered alongside tolerability, access and individual history.
Which symptoms to report
Nausea, vomiting, diarrhea or constipation can affect treatment continuity. Report difficulty eating or drinking and symptoms appearing after a change. Severe abdominal pain or a sudden loss of vision warrants prompt assessment.
What to bring to the decision
List previous treatments and why they were stopped. Mention digestive illness, eye history, other medicines and pregnancy plans. Ask what follow-up would be needed and how the decision would be reviewed if symptoms or access difficulties arise.
Review your situation with the doctor
Attend an in-person or virtual consultation with Dr. Teresita Cortés at Endomédicos to review your history, questions and follow-up. Bring available reports and a list of the products you use.
When to seek medical care
If symptoms persist, test results are abnormal, or you have questions about medication, arrange an individual assessment. Do not change treatment or doses without medical guidance.
Frequently asked questions
Is semaglutide safe for everyone with obesity?
Safety requires reviewing the formulation and your history. Attend a consultation to assess benefits and risks in your situation.
Can I switch from semaglutide to tirzepatide on my own?
A switch requires discussion of indication, tolerability and follow-up with your care team.
References
- Tirzepatide compared with semaglutide for obesity, SURMOUNT trial · New England Journal of Medicine
- Semaglutide and cardiovascular outcomes in obesity without diabetes · New England Journal of Medicine
- Wegovy, official prescribing information for injection and tablets · FDA
- GLP-1 medicines, updated safety information on a rare serious eye condition · FDA
Does this topic resonate with you?
Every case is different. Book a consultation to review your history, test results and goals with a personalized plan.


